CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
N-acetyl-l-cysteinedrug
Likely dose
N-acetyl-l-cysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01840345
NCT01840345Phase 2Completed
CompareCT.gov

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Virginia Commonwealth University·interventional·Posted Apr 25, 2013·Updated May 14, 2018

In Brief

A Phase 2 clinical trial evaluating N-acetyl-l-cysteine for Neuropathic Pain. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2013
Enrollment StartJan 1, 2014
Primary CompletionMar 1, 2017
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.2 years ago

Interventions

N-acetyl-l-cysteinedrug

1200 mg BID x 4 weeks